Taysha Gene Therapies (TSHA) Cash from Operations (2020 - 2026)

Taysha Gene Therapies has reported Cash from Operations for 7 years, with the latest figure at 40878000.0 in Q1 2026.

• Quarterly Cash from Operations fell 85.64% year-over-year to 40878000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 111948000.0 (down 34.15% YoY) and the FY2025 annual result came in at 93090000.0, down 14.61% from the prior year.
• Cash from Operations fell to 40878000.0 in Q1 2026 per TSHA's latest filing, from 26722000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 14712000.0 in Q4 2022 and troughed at 40939000.0 in Q1 2022.
• A 5-year average of 22153000.0 and a median of 21504000.0 in 2024 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations surged 136.54% in 2022, then plunged 209.55% in 2023.
• Over 5 years, Cash from Operations stood at 14712000.0 in 2022, then slumped by 209.55% to 16117000.0 in 2023, then fell by 13.59% to 18308000.0 in 2024, then slumped by 45.96% to 26722000.0 in 2025, then plunged by 52.98% to 40878000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 40878000.0, 26722000.0, and 24166000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.